<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM25878-4S3-R0-M96">
    <metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S2513 IS: OTC Monograph Drug User Fee Transparency Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-07-29</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
        <distribution-code display="yes">II</distribution-code>
        <congress>119th CONGRESS</congress>
        <session>1st Session</session>
        <legis-num>S. 2513</legis-num>
        <current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
        <action>
            <action-date date="20250729">July 29, 2025</action-date>
            <action-desc><sponsor name-id="S362">Mr. Kaine</sponsor> introduced the following bill;
                which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and
                Pensions</committee-name></action-desc>
        </action>
        <legis-type>A BILL</legis-type>
        <official-title>To amend the Federal Food, Drug, and Cosmetic Act with respect to
            transparency and reporting regarding over-the-counter drug monograph activities, and for
            other purposes.</official-title>
    </form>
    <legis-body>
        <section id="S1" section-type="section-one">
            <enum>1.</enum>
            <header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>OTC Monograph Drug User Fee Transparency Act</short-title></quote>.</text>
        </section>
        <section commented="no" display-inline="no-display-inline" id="H8B16CA9BA9DF49DDA439CB35CBC88377">
            <enum>2.</enum>
            <header>OTC monograph drug performance reports</header>
            <subsection commented="no" display-inline="no-display-inline" id="id966585f62b8b47ae8d41f77be719b833">
                <enum>(a)</enum>
                <header display-inline="yes-display-inline">Performance report</header>
 <text display-inline="yes-display-inline">Section 744N of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-73">21 U.S.C. 379j–73</external-xref>) is amended—</text>
                <paragraph commented="no" display-inline="no-display-inline" id="id93820f93c8a141b3accc2f9510ef3cd2">
                    <enum>(1)</enum>
 <text>in subsection (a)—</text> <subparagraph commented="no" display-inline="no-display-inline" id="id82f171faeeb04ef495bcc5f58f53f01e"> <enum>(A)</enum> <text display-inline="yes-display-inline">by striking <quote>Beginning with</quote> and inserting the following:</text>
                        <quoted-block style="OLC" display-inline="no-display-inline" id="idfc9a05ea1dbb4617a0acf17ec04dbddc">
                            <paragraph id="id7f41da33c2124536abb1cc6317747532">
                                <enum>(1)</enum>
                                <header>In general</header>
 <text>Beginning with</text> </paragraph> <after-quoted-block>; </after-quoted-block> </quoted-block> </subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="id1f8df89aba234b15a54ba99b6b3ac7b9"> <enum>(B)</enum> <text>by striking <quote>section 3861(b)</quote> and inserting <quote>section 3861</quote>; and</text>
                    </subparagraph>
                    <subparagraph id="id1fdca7c964ef49459b6565cb66a832c3" commented="no" display-inline="no-display-inline">
                        <enum>(C)</enum>
 <text>by adding at the end the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="iddb23125f30804e6e978fb6ecaa71520a"> <paragraph id="id2b626feb60814d728e9f6b90166c57d8"> <enum>(2)</enum> <header>Additional information</header> <text>Beginning with fiscal year 2026, the annual report under this subsection shall include—</text>
                                <subparagraph commented="no" display-inline="no-display-inline" id="idfe6d132cac1a43d4bea33409aaea71bf">
                                    <enum>(A)</enum>
 <text display-inline="yes-display-inline">the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—</text>
                                    <clause commented="no" display-inline="no-display-inline" id="id5af8a33cd997492dbc07e0e51187f46c">
                                        <enum>(i)</enum>
 <text display-inline="yes-display-inline">the number of Tier 1 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;</text>
                                    </clause>
                                    <clause commented="no" display-inline="no-display-inline" id="id1a90edffdbf44904aca6864122ff3e8b">
                                        <enum>(ii)</enum>
 <text display-inline="yes-display-inline">the number of Tier 2 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;</text>
                                    </clause>
                                    <clause commented="no" display-inline="no-display-inline" id="id9f252c2007fb4c1a804b09f6aece5c84">
                                        <enum>(iii)</enum>
 <text display-inline="yes-display-inline">the number of specified safety OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year; </text>
                                    </clause>
                                    <clause commented="no" display-inline="no-display-inline" id="id47a6ee234e2840b99337897e5c0c1fba">
                                        <enum>(iv)</enum>
 <text display-inline="yes-display-inline">the number of generally recognized as safe and effective finalization OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;</text>
                                    </clause>
                                    <clause commented="no" display-inline="no-display-inline" id="id3ebf8c9599104ce5bbe4277fc69f0f45">
                                        <enum>(v)</enum>
 <text display-inline="yes-display-inline">the average timeline for processing OTC monograph order requests, in the aggregate and by submission type, in the previous fiscal year; and</text>
                                    </clause>
                                    <clause id="ida0c458a24a1441e1a4fa27eeb6ae388f">
                                        <enum>(vi)</enum>
 <text>postmarket safety activities with respect to OTC monograph drugs, including— </text>
                                        <subclause commented="no" display-inline="no-display-inline" id="idf58671b500904665bead05c4dc58c0b2">
                                            <enum>(I)</enum>
 <text display-inline="yes-display-inline">collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;</text>
                                        </subclause>
                                        <subclause commented="no" display-inline="no-display-inline" id="id319b79ec7bd149d0811d5d46dd271c99">
                                            <enum>(II)</enum>
 <text display-inline="yes-display-inline">developing and using improved analytical tools, adverse event data-collection systems, including information technology systems, to assess potential safety problems, including access to external databases; and</text>
                                        </subclause>
                                        <subclause commented="no" display-inline="no-display-inline" id="idc07bbae92b0d47e0be7a0baa1581d718">
                                            <enum>(III)</enum>
 <text>activities under section 760; and</text> </subclause> </clause> </subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="id839790f2d2c84531bf3671df41b8a244"> <enum>(B)</enum> <text>information regarding registration of OTC monograph drug facilities and contract manufacturing organization facilities and payment of registration fees by such facilities, including—</text>
                                    <clause commented="no" display-inline="no-display-inline" id="ide5549a9e0286437f81c207bed8535fc7">
                                        <enum>(i)</enum>
 <text display-inline="yes-display-inline">the OTC monograph drug facilities and contract manufacturing organization facilities that were first registered under section 510(c) or 510(i) in the fiscal year; and</text>
                                    </clause>
                                    <clause commented="no" display-inline="no-display-inline" id="id4171de0ea9d943bd8bea4fa679f019a3">
                                        <enum>(ii)</enum>
 <text display-inline="yes-display-inline">for each OTC monograph drug facility and contract manufacturing organization facility that was assessed a facility fee under section 744M(a) in the fiscal year, whether the facility paid such fee.</text>
                                    </clause>
                                </subparagraph>
                            </paragraph>
                            <paragraph commented="no" display-inline="no-display-inline" id="id1c67a464c7f84df0ac105a6d115acb2c">
                                <enum>(3)</enum>
                                <header>Confidentiality</header>
 <text display-inline="yes-display-inline">Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of this Act or section 1905 of title 18, United States Code, or that is subject to withholding under section 552(b)(4) of title 5, United States Code.</text>
                            </paragraph>
                            <after-quoted-block>; and</after-quoted-block>
                        </quoted-block>
                    </subparagraph>
                </paragraph>
                <paragraph commented="no" display-inline="no-display-inline" id="H2EF8F5135B5E48D2BB080C4C67DFFF1E">
                    <enum>(2)</enum>
 <text>by adding at the end of subsection (d) the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="idaacf4ab40e1a4d7ba1514d250b97fdc4"> <paragraph id="ID3E07D73433E345109FD94AC8D201FA1E" commented="no" display-inline="no-display-inline"> <enum>(4)</enum> <header display-inline="yes-display-inline">Minutes of negotiation meetings</header> <subparagraph id="ID6D73F2D1C95540A9B2C7E3BF53A15DD0" commented="no" display-inline="no-display-inline"> <enum>(A)</enum> <header>Public availability</header> <text>The Secretary shall make publicly available, on the public website of the Food and Drug Administration, robust written minutes of all negotiation meetings conducted under this subsection between the Food and Drug Administration and the regulated industry, not later than 30 days after each such negotiation meeting.</text>
                            </subparagraph>
                            <subparagraph id="IDD1E5D08F10C8408BA3774F6E5F15DCA3" commented="no" display-inline="no-display-inline">
                                <enum>(B)</enum>
                                <header>Content</header>
 <text>The robust written minutes described under subparagraph (A) shall contain, in detail, any substantive proposal made by any party to the negotiations as well as significant controversies or differences of opinion during the negotiations and their resolution.</text>
                            </subparagraph>
                        </paragraph>
                        <after-quoted-block>.</after-quoted-block>
                    </quoted-block>
                </paragraph>
            </subsection>
            <subsection commented="no" display-inline="no-display-inline" id="idb6aa6f74af684d3f9cbdd7ac331ee67e">
                <enum>(b)</enum>
                <header>GAO report</header>
                <paragraph id="id7c5bc9bd098746ac847d5254f7f551d6">
                    <enum>(1)</enum>
                    <header>In general</header>
 <text>Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report assessing the supply chain of over-the-counter monograph drugs.</text>
                </paragraph>
                <paragraph id="id82da79282d9e4ed2bad8499bf22ba2f8">
                    <enum>(2)</enum>
                    <header>Contents</header>
 <text>The report required under paragraph (1) shall include an assessment of—</text>
                    <subparagraph id="id1402e8bbf2f44ff9bccd9f5d74ee007d">
                        <enum>(A)</enum>
 <text>information the Food and Drug Administration and others have reported about the overall stability of the supply chain of over-the-counter monograph drugs;</text>
                    </subparagraph>
                    <subparagraph commented="no" display-inline="no-display-inline" id="id454de9bde36449619195ddd7c5c6c4a2">
                        <enum>(B)</enum>
 <text display-inline="yes-display-inline">what information is collected by the Food and Drug Administration with respect to the supply chain of over-the-counter monograph drugs;</text>
                    </subparagraph>
                    <subparagraph id="id208bd2a477ea4c29a911ff72f6a1b13d">
                        <enum>(C)</enum>
 <text>how the Food and Drug Administration uses information collected on the supply chain of over-the-counter monograph drugs to inform regulatory decisions;</text>
                    </subparagraph>
                    <subparagraph id="idafd698f3b7664410973e8a58b27cdf90">
                        <enum>(D)</enum>
 <text>how the Food and Drug Administration coordinates with other Federal agencies to monitor and mitigate disruptions to the supply chain of over-the-counter monograph drugs; and</text>
                    </subparagraph>
                    <subparagraph id="id697b1ea7a07b4ddbb4fc421b5f6f9602">
                        <enum>(E)</enum>
 <text>the unique characteristics of the over-the-counter monograph drug marketplace and what additional authorities or information, if any, the Food and Drug Administration and others have identified as being necessary to ensure the stability of the supply chain of over-the-counter monograph drugs.</text>
                    </subparagraph>
                </paragraph>
            </subsection>
        </section>
    </legis-body>
</bill>

